Close Menu

Atlas Ventures

The firms announced a deal to identify strategic investments in technology areas within agriculture "to support and complement Monsanto's interests and potential growth areas."

The startup has now raised a total of $26 million in Series A financing to support development of a biomarker-based cancer diagnostic.

The new preliminary prospectus offers for sale around 9.6 million shares by shareholders of the firm. Helicos won't receive any proceeds from the sale.

Short Reads

Premium

Life Technologies, Max Planck Institute for Evolutionary Anthropology, 454 Life Sciences, Applied Biosystems, Baylor College of Medicine, University of Bristol, University of Liverpool, John Innes Centre, Helicos BioSciences, Febit, and more…

Helicos filed the prospectus for 68.4 million shares held by investors who participated in a private placement in December. The firm would receive none of the proceeds from the sale of those shares, if any of them are sold.

Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.

The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.

Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.

In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.